Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.

× No keyword cloud information.

4 in total

1. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.

Authors: Julien Calderaro; Benoît Rousseau; Giuliana Amaddeo; Marion Mercey; Cécile Charpy; Charlotte Costentin; Alain Luciani; Elie-Serge Zafrani; Alexis Laurent; Daniel Azoulay; Fouad Lafdil; Jean-Michel Pawlotsky
Journal: Hepatology Date: 2016-08-09 Impact factor: 17.425

Review 2. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.

Authors: Tai Hato; Andrew X Zhu; Dan G Duda
Journal: Immunotherapy Date: 2016-02-11 Impact factor: 4.196

3. Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.

Authors: Mei-Ling Chen; Bo-Shiun Yan; Wan-Chih Lu; Mei-Huei Chen; Sung-Liang Yu; Pan-Chyr Yang; Ann-Lii Cheng
Journal: Int J Cancer Date: 2013-07-30 Impact factor: 7.396

4. Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.

Authors: Mengde Cao; Yiling Xu; Je-in Youn; Roniel Cabrera; Xiaokui Zhang; Dmitry Gabrilovich; David R Nelson; Chen Liu
Journal: Lab Invest Date: 2011-02-14 Impact factor: 5.662

4 in total

7 in total

1. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.

Authors: Ioannis A Ziogas; Alexandros P Evangeliou; Lipika Goyal; Georgios Tsoulfas; Dimitrios Giannis; Muhammad H Hayat; Konstantinos S Mylonas; Samer Tohme; David A Geller; Nahel Elias
Journal: Oncologist Date: 2021-01-02

2. Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study.

Authors: Chia-Yang Hsu; Po-Hong Liu; Shu-Yein Ho; Yi-Hsiang Huang; Yun-Hsuan Lee; Yi-You Chiou; Ting-Hui Hsieh; Tom Fang; Ya-Ju Tsai; Ming-Chih Hou; Teh-Ia Huo
Journal: PLoS One Date: 2017-11-10 Impact factor: 3.240

3. Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review.

Authors: Ling Gao; Xi Yang; Cheng Yi; Hong Zhu
Journal: Front Pharmacol Date: 2019-10-17 Impact factor: 5.810

4. Impact of self-decision to stop cancer treatment on advanced genitourinary cancer patients.

Authors: Hisato Kobayashi; Katsuki Tsuchiyama; Minekatsu Taga; Takahiro Tokunaga; Hideaki Ito; Osamu Yokoyama
Journal: Medicine (Baltimore) Date: 2021-04-09 Impact factor: 1.817

5. Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study.

Authors: San-Chi Chen; Yi-Hsiang Huang; Ming-Huang Chen; Yi-Ping Hung; Rheun-Chuan Lee; Yu-Yun Shao; Yee Chao
Journal: BMC Cancer Date: 2022-01-11 Impact factor: 4.430

6. Efficacy and safety of camrelizumab plus transarterial chemoembolization in intermediate to advanced hepatocellular carcinoma patients: A prospective, multi-center, real-world study.

Authors: Ran You; Qingyu Xu; Qi Wang; Qingqiao Zhang; Weizhong Zhou; Chi Cao; Xiangzhong Huang; Honghai Ji; Penghua Lv; Hao Jiang; You Lu; Yong Jin; Yongjun Li; Long Cheng; Weidong Wang; Hao Xu; Xiaoli Zhu; Guowen Yin
Journal: Front Oncol Date: 2022-08-02 Impact factor: 5.738

Review 7. Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer?

Authors: Elena García-Martínez; Andres Redondo; Josep Maria Piulats; Analía Rodríguez; Antonio Casado
Journal: Angiogenesis Date: 2020-07-20 Impact factor: 9.596

7 in total